Trial · NCT05205668
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of subjects with any treatment-emergent adverse events (TEAEs) during the study | Day 1 to Day 60/End of Study (EOS) | |
| Secondary | Proportion (%) of subjects with any serious adverse events (SAEs) and drug-related adverse events (AEs) during the study | Day 1 to Day 60/EOS | |
| Secondary | Proportion (%) of subjects with clinically significant abnormality in clinical laboratory tests and ECG during the study | Day 1 to Day 28 | |
| Secondary | Change in parameters for coagulopathy including D-dimer, fibrinogen, coagulation tests and platelet count during the study | Day 1 to Day 28 | |
| Secondary | Change in parameters of cardiac function including N-terminal-pro hormone brain natriuretic peptide (NT-proBNP) or brain natriuretic peptide (BNP) and high-sensitivity cardiac troponin (or troponin) during the study | Day 1 to Day 28 | |
| Secondary | Serum concentration of F-652 at specified timepoints | At predefined timepoints from Day 1 to Day 14/End of Treatment (EOT) | |
| Secondary | Number of days with oxygen use during the treatment period | Day 1 to Day 14/EOT | |
| Secondary | Change in the World Health Organization (WHO) 10-point ordinal scale during the study period | Day 1 to Day 14/EOT and Day 28 | The World Health Organization 10-point ordinal scale is developed by a special committee at WHO to measure illness severity over time. The minimum value is 0, the maximum value is 10. Severity increases as the score increases. A 2-point reduction on the score is considered as clinical improvement. |
| Secondary | Number of days hospitalized during the treatment period | Day 1 to Day 14/EOT | |
| Secondary | Proportion (%) of subjects alive and free of respiratory failure during the study period | Day 1 to Day 14/EOT, Day 28, and Day 60/EOS | |
| Secondary | All-cause mortality rate during the study period | Day 1 to Day 14/EOT, Day 28, and Day 60/EOS | |
| Other | Exploratory Endpoints - biomarkers | Day 1 to Day 14/EOT | Changes in biomarkers mainly indicative of lung injury and inflammation |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05205668/registered